BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Davies NM, Watson MS. Clinical pharmacokinetics of sulindac. A dynamic old drug. Clin Pharmacokinet 1997;32:437-59. [PMID: 9195115 DOI: 10.2165/00003088-199732060-00002] [Cited by in Crossref: 51] [Cited by in F6Publishing: 48] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Rautio J, Kumpulainen H, Heimbach T, Oliyai R, Oh D, Järvinen T, Savolainen J. Prodrugs: design and clinical applications. Nat Rev Drug Discov. 2008;7:255-270. [PMID: 18219308 DOI: 10.1038/nrd2468] [Cited by in Crossref: 880] [Cited by in F6Publishing: 777] [Article Influence: 62.9] [Reference Citation Analysis]
2 Steinbrink SD, Pergola C, Bühring U, George S, Metzner J, Fischer AS, Häfner A, Wisniewska JM, Geisslinger G, Werz O, Steinhilber D, Maier TJ. Sulindac sulfide suppresses 5-lipoxygenase at clinically relevant concentrations. Cell Mol Life Sci 2010;67:797-806. [DOI: 10.1007/s00018-009-0206-0] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
3 Rodriguez-aller M, Guillarme D, Veuthey J, Gurny R. Strategies for formulating and delivering poorly water-soluble drugs. Journal of Drug Delivery Science and Technology 2015;30:342-51. [DOI: 10.1016/j.jddst.2015.05.009] [Cited by in Crossref: 62] [Cited by in F6Publishing: 33] [Article Influence: 8.9] [Reference Citation Analysis]
4 Márquez Loza A, Elias V, Wong CP, Ho E, Bermudez M, Magnusson KR. Effects of ibuprofen on cognition and NMDA receptor subunit expression across aging. Neuroscience 2017;344:276-92. [PMID: 28057539 DOI: 10.1016/j.neuroscience.2016.12.041] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
5 Piazza GA, Keeton AB, Tinsley HN, Gary BD, Whitt JD, Mathew B, Thaiparambil J, Coward L, Gorman G, Li Y. A novel sulindac derivative that does not inhibit cyclooxygenases but potently inhibits colon tumor cell growth and induces apoptosis with antitumor activity. Cancer Prev Res (Phila). 2009;2:572-580. [PMID: 19470791 DOI: 10.1158/1940-6207.CAPR-09-0001] [Cited by in Crossref: 64] [Cited by in F6Publishing: 53] [Article Influence: 4.9] [Reference Citation Analysis]
6 Berg AK, Mandrekar SJ, Ziegler KL, Carlson EC, Szabo E, Ames MM, Boring D, Limburg PJ, Reid JM; Cancer Prevention Network. Population pharmacokinetic model for cancer chemoprevention with sulindac in healthy subjects. J Clin Pharmacol 2013;53:403-12. [PMID: 23436338 DOI: 10.1002/jcph.26] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
7 Piazza GA, Keeton AB, Tinsley HN, Whitt JD, Gary BD, Mathew B, Singh R, Grizzle WE, Reynolds RC. NSAIDs: Old Drugs Reveal New Anticancer Targets. Pharmaceuticals (Basel) 2010;3:1652-67. [PMID: 27713322 DOI: 10.3390/ph3051652] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 2.8] [Reference Citation Analysis]
8 Tinsley HN, Gary BD, Thaiparambil J, Li N, Lu W, Li Y, Maxuitenko YY, Keeton AB, Piazza GA. Colon tumor cell growth-inhibitory activity of sulindac sulfide and other nonsteroidal anti-inflammatory drugs is associated with phosphodiesterase 5 inhibition. Cancer Prev Res (Phila) 2010;3:1303-13. [PMID: 20876730 DOI: 10.1158/1940-6207.CAPR-10-0030] [Cited by in Crossref: 53] [Cited by in F6Publishing: 30] [Article Influence: 4.4] [Reference Citation Analysis]
9 Reid JM, Mandrekar SJ, Carlson EC, Harmsen WS, Green EM, McGovern RM, Szabo E, Ames MM, Boring D, Limburg PJ; Cancer Prevention Network. Comparative bioavailability of sulindac in capsule and tablet formulations. Cancer Epidemiol Biomarkers Prev 2008;17:674-9. [PMID: 18349286 DOI: 10.1158/1055-9965.EPI-07-2510] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
10 Zhao YH, Le J, Abraham MH, Hersey A, Eddershaw PJ, Luscombe CN, Boutina D, Beck G, Sherborne B, Cooper I, Platts JA. Evaluation of human intestinal absorption data and subsequent derivation of a quantitative structure–activity relationship (QSAR) with the Abraham descriptors. Journal of Pharmaceutical Sciences 2001;90:749-84. [DOI: 10.1002/jps.1031] [Cited by in Crossref: 333] [Cited by in F6Publishing: 287] [Article Influence: 15.9] [Reference Citation Analysis]
11 Ye X, Wu H, Sheng L, Liu YX, Ye F, Wang M, Zhou H, Su Y, Zhang XK. Oncogenic potential of truncated RXRα during colitis-associated colorectal tumorigenesis by promoting IL-6-STAT3 signaling. Nat Commun 2019;10:1463. [PMID: 30931933 DOI: 10.1038/s41467-019-09375-8] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 8.0] [Reference Citation Analysis]
12 Yasui H, Adachi M, Imai K. Combination of tumor necrosis factor-alpha with sulindac augments its apoptotic potential and suppresses tumor growth of human carcinoma cells in nude mice. Cancer. 2003;97:1412-1420. [PMID: 12627504 DOI: 10.1002/cncr.11210] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.1] [Reference Citation Analysis]
13 Sanoh S, Naritomi Y, Fujimoto M, Sato K, Kawamura A, Horiguchi A, Sugihara K, Kotake Y, Ohshita H, Tateno C, Horie T, Kitamura S, Ohta S. Predictability of plasma concentration–time curves in humans using single-species allometric scaling of chimeric mice with humanized liver. Xenobiotica 2015;45:605-14. [DOI: 10.3109/00498254.2015.1007112] [Cited by in Crossref: 32] [Cited by in F6Publishing: 21] [Article Influence: 4.6] [Reference Citation Analysis]
14 Curiel-Lewandrowski C, Swetter SM, Einspahr JG, Hsu CH, Nagle R, Sagerman P, Tangrea J, Parnes H, Alberts DS, Chow HH. Randomized, double-blind, placebo-controlled trial of sulindac in individuals at risk for melanoma: evaluation of potential chemopreventive activity. Cancer 2012;118:5848-56. [PMID: 22605570 DOI: 10.1002/cncr.27540] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
15 Haroon M, Abdulazeez I, Saleh TA, Al-saadi AA. SERS-based trace-level quantification of sulindac: Spectroscopic and molecular modeling evaluation. Journal of Molecular Liquids 2020;312:113402. [DOI: 10.1016/j.molliq.2020.113402] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 4.5] [Reference Citation Analysis]
16 Kumar V, Bharate SS, Vishwakarma RA. Modulating lipophilicity of rohitukine via prodrug approach: Preparation, characterization, and in vitro enzymatic hydrolysis in biorelevant media. European Journal of Pharmaceutical Sciences 2016;92:203-11. [DOI: 10.1016/j.ejps.2016.07.010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
17 Heimbach T, Fleisher D, Kaddoumi A. Overcoming Poor Aqueous Solubility of Drugs for Oral Delivery. In: Stella VJ, Borchardt RT, Hageman MJ, Oliyai R, Maag H, Tilley JW, editors. Prodrugs. New York: Springer; 2007. pp. 157-215. [DOI: 10.1007/978-0-387-49785-3_5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Reference Citation Analysis]
18 Fogli S, Banti I, Stefanelli F, Picchianti L, Digiacomo M, Macchia M, Breschi MC, Lapucci A. Therapeutic potential of sulindac hydroxamic acid against human pancreatic and colonic cancer cells. European Journal of Medicinal Chemistry 2010;45:5100-7. [DOI: 10.1016/j.ejmech.2010.08.019] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
19 Perez-ruiz F, Mielgo FJ, Herrero Beites AM. Optimisation of the Treatment of Acute Gout: . BioDrugs 2000;13:415-23. [DOI: 10.2165/00063030-200013060-00005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
20 Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA. 1999;96:7563-7568. [PMID: 10377455 DOI: 10.1073/pnas.96.13.7563] [Cited by in Crossref: 1044] [Cited by in F6Publishing: 923] [Article Influence: 45.4] [Reference Citation Analysis]
21 Garrido W, Muñoz M, San Martín R, Quezada C. FK506 confers chemosensitivity to anticancer drugs in glioblastoma multiforme cells by decreasing the expression of the multiple resistance-associated protein-1. Biochemical and Biophysical Research Communications 2011;411:62-8. [DOI: 10.1016/j.bbrc.2011.06.087] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
22 Moon Y, Kim JI, Yang H, Eling TE. Growth compensatory role of sulindac sulfide-induced thrombospondin-1 linked with ERK1/2 and RhoA GTPase signaling pathways. Life Sci 2008;82:591-9. [PMID: 18261746 DOI: 10.1016/j.lfs.2007.11.030] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
23 Wang ZG, Chen L, Chen J, Zheng JF, Gao W, Zeng Z, Zhou H, Zhang XK, Huang PQ, Su Y. Synthesis and SAR study of modulators inhibiting tRXRα-dependent AKT activation. Eur J Med Chem 2013;62:632-48. [PMID: 23434637 DOI: 10.1016/j.ejmech.2013.01.012] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
24 Broadbent AM, Heaney A, Weyman K. A Review of Short Bowel Syndrome and Palliation: A Case Report and Medication Guideline. Journal of Palliative Medicine 2006;9:1481-91. [DOI: 10.1089/jpm.2006.9.1481] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
25 Zhu H, Dronamraju V, Xie W, More SS. Sulfur-containing therapeutics in the treatment of Alzheimer's disease. Med Chem Res 2021;30:305-52. [PMID: 33613018 DOI: 10.1007/s00044-020-02687-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Hay MP, Wilson WR, Denny WA. Design, Synthesis and Evaluation of Imidazolylmethyl Carbamate Prodrugs of Alkylating Agents. Tetrahedron 2000;56:645-57. [DOI: 10.1016/s0040-4020(99)01031-5] [Cited by in Crossref: 27] [Article Influence: 1.2] [Reference Citation Analysis]
27 Tinsley HN, Gary BD, Keeton AB, Zhang W, Abadi AH, Reynolds RC, Piazza GA. Sulindac sulfide selectively inhibits growth and induces apoptosis of human breast tumor cells by phosphodiesterase 5 inhibition, elevation of cyclic GMP, and activation of protein kinase G. Mol Cancer Ther 2009;8:3331-40. [PMID: 19996273 DOI: 10.1158/1535-7163.MCT-09-0758] [Cited by in Crossref: 63] [Cited by in F6Publishing: 43] [Article Influence: 5.3] [Reference Citation Analysis]
28 Varma MV, Panchagnula R. Prediction of in vivo intestinal absorption enhancement on P-glycoprotein inhibition, from rat in situ permeability. Journal of Pharmaceutical Sciences 2005;94:1694-704. [DOI: 10.1002/jps.20309] [Cited by in Crossref: 64] [Cited by in F6Publishing: 58] [Article Influence: 3.8] [Reference Citation Analysis]
29 Minagawa K, Berber MR, Hafez IH, Mori T, Tanaka M. Target delivery and controlled release of the chemopreventive drug sulindac by using an advanced layered double hydroxide nanomatrix formulation system. J Mater Sci Mater Med 2012;23:973-81. [PMID: 22350776 DOI: 10.1007/s10856-012-4566-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
30 Huang W, Shao L, Li S, Guo D, Wang L, Li Z, Peng X, Chen Y, Zhang W, Zhou H, Tan Z. Simultaneous determination of sulindac and its metabolites sulindac sulfide and sulindac sulfone in human plasma by a sensitive UPLC-PDA method for a pharmacokinetic study. Anal Methods 2014;6:4679-85. [DOI: 10.1039/c4ay00730a] [Cited by in Crossref: 4] [Article Influence: 0.5] [Reference Citation Analysis]
31 Sung JW, Yun HY, Park S, Kim YJ, Yee J, Lee KE, Song B, Chung JE, Gwak HS. Population Pharmacokinetics of Sulindac and Genetic Polymorphisms of FMO3 and AOX1 in Women with Preterm Labor. Pharm Res 2020;37:44. [PMID: 31993760 DOI: 10.1007/s11095-020-2765-6] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
32 Bock JM, Menon SG, Goswami PC, Sinclair LL, Bedford NS, Domann FE, Trask DK. Relative non-steroidal anti-inflammatory drug (NSAID) antiproliferative activity is mediated through p21-induced G1 arrest and E2F inhibition. Mol Carcinog 2007;46:857-64. [PMID: 17415779 DOI: 10.1002/mc.20318] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
33 Yang H, Park SH, Choi HJ, Moon Y. The integrated stress response-associated signals modulates intestinal tumor cell growth by NSAID-activated gene 1 (NAG-1/MIC-1/PTGF- ). Carcinogenesis 2010;31:703-11. [DOI: 10.1093/carcin/bgq008] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
34 Friedrich CA, Rader DJ. MANAGEMENT OF LIPID DISORDERS. Rheumatic Disease Clinics of North America 1999;25:507-20. [DOI: 10.1016/s0889-857x(05)70084-3] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
35 Koba M, Stasiak J, Bober L, Bączek T. Evaluation of molecular descriptors and HPLC retention data of analgesic and anti-inflammatory drugs by factor analysis in relation to their pharmacological activity. J Mol Model 2010;16:1319-31. [DOI: 10.1007/s00894-010-0647-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
36 Fernandes E, Toste SA, Lima JL, Reis S. The metabolism of sulindac enhances its scavenging activity against reactive oxygen and nitrogen species. Free Radical Biology and Medicine 2003;35:1008-17. [DOI: 10.1016/s0891-5849(03)00437-4] [Cited by in Crossref: 47] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
37 Mesches MH, Gemma C, Veng LM, Allgeier C, Young DA, Browning MD, Bickford PC. Sulindac improves memory and increases NMDA receptor subunits in aged Fischer 344 rats. Neurobiology of Aging 2004;25:315-24. [DOI: 10.1016/s0197-4580(03)00116-7] [Cited by in Crossref: 55] [Cited by in F6Publishing: 31] [Article Influence: 3.1] [Reference Citation Analysis]
38 Slováková A, von Maltzan XF, Patel BK, Drake AF, Hutt AJ. Chromatographic resolution, chiroptical characterization and urinary excretion of the enantiomers of sulindac. Chromatographia 1998;48:369-76. [DOI: 10.1007/bf02467706] [Cited by in Crossref: 6] [Article Influence: 0.3] [Reference Citation Analysis]
39 Chen L, Wang ZG, Aleshin AE, Chen F, Chen J, Jiang F, Alitongbieke G, Zeng Z, Ma Y, Huang M, Zhou H, Cadwell G, Zheng JF, Huang PQ, Liddington RC, Zhang XK, Su Y. Sulindac-derived RXRα modulators inhibit cancer cell growth by binding to a novel site. Chem Biol 2014;21:596-607. [PMID: 24704507 DOI: 10.1016/j.chembiol.2014.02.017] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 4.1] [Reference Citation Analysis]
40 O’Connor R, O’Leary M, Ballot J, Collins CD, Kinsella P, Mager DE, Arnold RD, O’Driscoll L, Larkin A, Kennedy S. A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer. Cancer Chemother Pharmacol. 2007;59:79-87. [PMID: 16642371 DOI: 10.1007/s00280-006-0240-7] [Cited by in Crossref: 26] [Cited by in F6Publishing: 33] [Article Influence: 1.6] [Reference Citation Analysis]
41 Stella VJ, Nti-Addae KW. Prodrug strategies to overcome poor water solubility. Adv Drug Deliv Rev 2007;59:677-94. [PMID: 17628203 DOI: 10.1016/j.addr.2007.05.013] [Cited by in Crossref: 330] [Cited by in F6Publishing: 288] [Article Influence: 22.0] [Reference Citation Analysis]
42 Lemmens G, Brouwers J, Snoeys J, Augustijns P, Vanuytsel T. Insight into the Colonic Disposition of Sulindac in Humans. J Pharm Sci 2021;110:259-67. [PMID: 33002468 DOI: 10.1016/j.xphs.2020.09.034] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
43 Whitt JD, Keeton AB, Gary BD, Sklar LA, Sodani K, Chen ZS, Piazza GA. Sulindac sulfide selectively increases sensitivity of ABCC1 expressing tumor cells to doxorubicin and glutathione depletion. J Biomed Res 2016;30:120-33. [PMID: 28276667 DOI: 10.7555/JBR.30.20150108] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
44 Gurpinar E, Grizzle WE, Piazza GA. COX-Independent Mechanisms of Cancer Chemoprevention by Anti-Inflammatory Drugs. Front Oncol. 2013;3:181. [PMID: 23875171 DOI: 10.3389/fonc.2013.00181] [Cited by in Crossref: 59] [Cited by in F6Publishing: 61] [Article Influence: 6.6] [Reference Citation Analysis]
45 Honey, Thareja S, Kumar M, Sinha V. Self-organizing molecular field analysis of NSAIDs: Assessment of pharmacokinetic and physicochemical properties using 3D-QSPkR approach. European Journal of Medicinal Chemistry 2012;53:76-82. [DOI: 10.1016/j.ejmech.2012.03.037] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
46 Li N, Xi Y, Tinsley HN, Gurpinar E, Gary BD, Zhu B, Li Y, Chen X, Keeton AB, Abadi AH. Sulindac selectively inhibits colon tumor cell growth by activating the cGMP/PKG pathway to suppress Wnt/β-catenin signaling. Mol Cancer Ther. 2013;12:1848-1859. [PMID: 23804703 DOI: 10.1158/1535-7163.mct-13-0048] [Cited by in Crossref: 69] [Cited by in F6Publishing: 51] [Article Influence: 7.7] [Reference Citation Analysis]
47 Moore RA, Derry S, McQuay HJ. Single dose oral sulindac for acute postoperative pain in adults. Cochrane Database Syst Rev 2009;:CD007540. [PMID: 19821425 DOI: 10.1002/14651858.CD007540.pub2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
48 Zbidah M, Lupescu A, Yang W, Bosc A, Jilani K, Shaik N, Lang F. Sulindac sulfide--induced stimulation of eryptosis. Cell Physiol Biochem 2012;30:1072-82. [PMID: 23202471 DOI: 10.1159/000341483] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]